Scottsdale, AZNCT06632457Now EnrollingIRB Ready

NASH Cirrhosis Clinical Trial in Scottsdale, AZ

Access cutting-edge nash cirrhosis treatment through this phase 3 clinical trial at a research site in Scottsdale. Study-provided care at no cost to qualified participants.

Sponsored by Boehringer Ingelheim

Quick Self-Assessment

See if you qualify for this Scottsdale location

Preparing your pre-screening questions…

Expert Care in Scottsdale

Access nash cirrhosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related nash cirrhosis treatment provided free

Apply for This Scottsdale Location

Check if you qualify for this nash cirrhosis clinical trial in Scottsdale, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Scottsdale

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Scottsdale site if eligible
  4. 4Begin participation

About This NASH Cirrhosis Study in Scottsdale

This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps peop

Sponsor: Boehringer Ingelheim

Who Can Participate

Inclusion Criteria

Male or female adults ≥18 years of age at the time of screening, and at least the legal age of consent in countries where it is \>18 years
Body mass index (BMI) ≥27 kg/m2(≥25 kg/m2 for Asian trial participants)
Compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
Magnetic resonance imaging proton density fat fraction (MRI-PDFF) fat fraction ≥5% or FibroScan® with controlled attenuation parameter (CAP) ≥288 dB/m, obtained during the screening period or a historic MRI-PDFF ≤12 weeks prior to randomisation (except for patients with 'cryptogenic cirrhosis' where MRI-PDFF \<5% or FibroScan® with CAP \<288 dB/m is allowed). This inclusion criterion does not apply for participants with a recent (≤12 months prior to randomisation) liver biopsy showing steatosis/steatohepatitis.
Further inclusion criteria apply.

Exclusion Criteria

Current or history (\<5 years) of significant alcohol consumption, defined as an average of \>140 g/week in female patients and \>210 g/week in male patients, for a period of \>3 consecutive months, or an inability to reliably quantify alcohol consumption based upon judgment of the investigator.
Model of end-stage liver Disease (MELD) score \>12 due to liver disease
History or current (i.e. at screening) hepatic decompensation event of any of the following but not limited to:
Portal hypertension-related upper gastrointestinal (GI) bleeding
Hepatic encephalopathy (HE) ≥Grade 1 according to the West Haven criteria
Any of the following lab test result at screening
Albumin below \<3.5 g/dL (\<35.0 g/L)
International normalised ratio (INR) \>1.3 unless due to therapeutic anticoagulants
Total bilirubin (TBL) \>1.2x upper limit of normal (ULN) NOTE: Trial participants with Gilbert Syndrome are eligible with a TBL \>1.2x ULN if reticulocyte count is within normal limits, haemoglobin is within normal limits unless due to chronic anaemia and unrelated to haemolysis, and direct bilirubin is \<20% of TBL.
Alkaline phosphatase \>1.5x ULN
PLT \<100,000/µL (\<100 GI/L)
History or evidence of other chronic liver diseases, such as primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis or overlap syndrome, Wilson's disease, alpha-1-antitrypsin deficiency, or genetic haemochromatosis
Hepatitis B positive (defined as positive hepatitis B surface antigen (HBsAg)) or history of chronic HBV infection
Hepatitis C positive (defined as positive hepatitis C virus (HCV) antibody and a positive HCV ribonucleic acid (RNA))
Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \>5x ULN
Evidence of alcoholic liver disease, or drug-induced liver disease, as defined on the basis of typical exposure and history
History of liver transplantation or listed for liver transplantation
History of transjugular intrahepatic portosystemic shunt (TIPS) or other radiological/surgical procedure for portal hypertension treatment
Further exclusion criteria apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Scottsdale?

Yes, this clinical trial (NCT06632457) has an active research site in Scottsdale, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

NASH Cirrhosis Treatment Options in Scottsdale, AZ

If you're searching for nash cirrhosis treatment options in Scottsdale, AZ, this clinical trial (NCT06632457) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Scottsdale research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced nash cirrhosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all nash cirrhosis clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Scottsdale, AZ

See all ankylosing spondylitis clinical trials recruiting in Scottsdale — not just this study.

Browse Ankylosing Spondylitis Trials in Scottsdale →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsNASH TrialsLiver Disease TrialsAll Conditions →

Ready to Join in Scottsdale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Scottsdale, AZ